@entity201 is a rare @entity5 originating in the bile ducts, which, according to their anatomical location, is classified as intrahepatic, extrahepatic and hilar. Nevertheless, incidence rates have increased markedly in recent decades. With respect to @entity5 biology, several genetic alterations correlated with resistance to chemotherapy and radiotherapy have been identified. Here, we highlight changes in @entity984 and @entity876 genes that are normally associated with a more @entity146 phenotype. Also @entity650 and some proteins of the @entity588 family appear to be involved in the resistance that the @entity201 presents toward conventional therapies. With regard to diagnosis, @entity5 markers most commonly used are CEA and CA 19-9, and although its use isolated appears controversial, their combined value has been increasingly advocated. In imaging terms, various methods are needed, such as abdominal ultrasound, computed tomography and cholangiopancreatography. Regarding therapy, surgical modalities are the only ones that offer chance of cure; however, due to late diagnosis, most @entity1 cannot take advantage of them. Thus, the majority of @entity1 are directed to other therapeutic modalities like chemotherapy, which, in this context, assumes a purely palliative role. Thus, it becomes urgent to investigate new therapeutic options for this highly @entity146 type of @entity5 .

XXXX : from molecular biology to treatment.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity650 :: ('3569', 'Gene') :: ['IL-6'] @entity588 :: ('596', 'Gene') :: ['BCL-2'] @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity984 :: ('3845', 'Gene') :: ['KRAS'] @entity876 :: ('7157', 'Gene') :: ['TP53'] @entity201 :: ('MESH:D018281', 'Disease') :: ['cholangiocarcinoma', 'Cholangiocarcinoma']
@entity201 :: (MESH:D018281,Disease) :: ['Cholangiocarcinoma']
